Login to Your Account

Earnings Roundup

Tuesday, April 19, 2011
Amylin Pharmaceuticals Inc., of San Diego, reported first quarter total revenue of $152.7 million on net product sales of $150.8 million, including $128 million for Byetta and $22.8 million for Symlin (pramlintide acetate), both for diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription